AR and breast cancer: In a Phase II clinical trial using bicalutamide in patients with AR-positive and ER/PR-negative metastatic BC the most commonly reported adverse events were fatigue, hot flushes, limb oedema, and aspartate aminotransferase (AST) and alkaline aminotransferase (ALT) elevation (Gucalp et al., 2013).